Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 23, 2017

DrugPatentWatch Database Preview

Details for Patent: RE38628

« Back to Dashboard

Summary for Patent: RE38628

Title: Pharmaceutical compositions
Abstract:A method of treatment of a condition selected from the group comprising conjunctivitis, keratitis, `allergic eyes`, adenovirus infections, corneal homograft rejection, anterior uveitis, nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx, reversible obstructive airways disease, Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution containing, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rboxylic acid or a pharmaceutically acceptable salt thereof. Also described are novel pharmaceutical compositions suitable for use in such methods of treatment.
Inventor(s): Clark; Andrew R. (Half Moon Bay, CA), Wright; Paul (Bramcote, GB), Ratcliffe; Julia H. (Woodbridge, GB)
Assignee: Fisons plc (Ipswich, GB)
Application Number:08/916,578
Patent Claim Types:
see list of patent claims
Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: RE38628

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8630767Dec 23, 1986
United Kingdom8630769Dec 23, 1986
United Kingdom8630904Dec 24, 1986
United Kingdom8706684Mar 20, 1987

International Patent Family for Patent: RE38628

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany3787274► Subscribe
Denmark680787► Subscribe
Denmark175032► Subscribe
European Patent Office0279121► Subscribe
European Patent Office0555717► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus